PL368319A1 - Kompozycje farmaceutyczne zawierające koniugaty polisacharydowe do hamowania przerzutów lub zapobiegania nawrotowi raka złośliwego - Google Patents

Kompozycje farmaceutyczne zawierające koniugaty polisacharydowe do hamowania przerzutów lub zapobiegania nawrotowi raka złośliwego

Info

Publication number
PL368319A1
PL368319A1 PL02368319A PL36831902A PL368319A1 PL 368319 A1 PL368319 A1 PL 368319A1 PL 02368319 A PL02368319 A PL 02368319A PL 36831902 A PL36831902 A PL 36831902A PL 368319 A1 PL368319 A1 PL 368319A1
Authority
PL
Poland
Prior art keywords
ofmaligant
metastsis
recurrence
tumor
inhibiting
Prior art date
Application number
PL02368319A
Other languages
English (en)
Inventor
Takayuki Kawaguchi
Satoshi Okuno
Toshiro Yano
Original Assignee
Tanabe Seiyaku Co, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co, Ltd. filed Critical Tanabe Seiyaku Co, Ltd.
Publication of PL368319A1 publication Critical patent/PL368319A1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PL02368319A 2001-08-21 2002-08-16 Kompozycje farmaceutyczne zawierające koniugaty polisacharydowe do hamowania przerzutów lub zapobiegania nawrotowi raka złośliwego PL368319A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001249717 2001-08-21

Publications (1)

Publication Number Publication Date
PL368319A1 true PL368319A1 (pl) 2005-03-21

Family

ID=19078678

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02368319A PL368319A1 (pl) 2001-08-21 2002-08-16 Kompozycje farmaceutyczne zawierające koniugaty polisacharydowe do hamowania przerzutów lub zapobiegania nawrotowi raka złośliwego

Country Status (18)

Country Link
EP (1) EP1418947A1 (pl)
KR (1) KR20040027972A (pl)
CN (1) CN100372570C (pl)
AR (1) AR035137A1 (pl)
AU (1) AU2002328093B2 (pl)
BR (1) BR0212036A (pl)
CA (1) CA2457056C (pl)
HU (1) HUP0401351A3 (pl)
IL (1) IL160148A0 (pl)
MX (1) MXPA04001599A (pl)
NO (1) NO20041194L (pl)
NZ (1) NZ530947A (pl)
PL (1) PL368319A1 (pl)
RU (1) RU2275913C2 (pl)
TW (1) TWI313609B (pl)
UA (1) UA75450C2 (pl)
WO (1) WO2003015826A1 (pl)
ZA (1) ZA200400917B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
RU2283848C1 (ru) * 2005-06-16 2006-09-20 Институт нефтехимии и катализа РАН Республика Башкортостан Способ получения конъюгатов альгиновой кислоты
FR2914305B1 (fr) * 2007-03-29 2009-07-03 Proteins & Peptides Man Dextran fonctionnalise par des amino-acides hydrophobes.
RU2320334C1 (ru) * 2006-08-07 2008-03-27 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО НижГМА Росздрава) Средство для ингибирования роста опухоли и способ ингибирования роста опухоли в эксперименте
RU2359975C2 (ru) * 2007-04-04 2009-06-27 Институт нефтехимии и катализа РАН Способ получения модифицированных арабиногалактанов
ES2672201T3 (es) 2008-07-16 2018-06-13 Children's Medical Center Corporation Dispositivo de imitación de órganos con microcanales y métodos de uso
AU2012262139B2 (en) * 2011-06-02 2017-02-23 Children's Medical Center Corporation Methods and uses for ex vivo tissue culture systems
PL221351B1 (pl) 2012-03-14 2016-03-31 Politechnika Warszawska Sposób otrzymywania nanocząstek polisacharydowych
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
WO2014061277A1 (ja) * 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート
IL310627B2 (en) 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
MY182282A (en) 2015-05-04 2021-01-18 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
JP6679762B2 (ja) 2017-01-17 2020-04-15 第一三共株式会社 抗gpr20抗体及び抗gpr20抗体−薬物コンジュゲート
TW202532104A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體-藥物結合物及其用途
CA3074208C (en) 2017-08-31 2023-10-03 Daiichi Sankyo Company, Limited Novel method for producing antibody-drug conjugate
IL324591A (en) 2017-08-31 2026-01-01 Daiichi Sankyo Co Ltd Improved antibody-drug conjugate production methods
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
WO2020022475A1 (ja) 2018-07-27 2020-01-30 第一三共株式会社 抗体-薬物コンジュゲートの薬物部位を認識する蛋白質
CA3108044A1 (en) 2018-07-31 2020-02-06 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of antibody-drug conjugate
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2149867T3 (es) * 1993-02-26 2000-11-16 Drug Delivery System Inst Ltd Derivados de polisacaridos y soportes para farmacos.
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
WO1997038727A1 (en) * 1996-04-15 1997-10-23 Asahi Kasei Kogyo Kabushiki Kaisha Medicament composite
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
CN1058038C (zh) * 1996-12-31 2000-11-01 中国科学院感光化学研究所 低收缩性光固化涂层材料及其制法和用途
EA003398B1 (ru) * 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Лекарственный комплекс c полимерным носителем

Also Published As

Publication number Publication date
RU2004108141A (ru) 2005-04-20
KR20040027972A (ko) 2004-04-01
UA75450C2 (en) 2006-04-17
IL160148A0 (en) 2004-07-25
EP1418947A1 (en) 2004-05-19
HUP0401351A3 (en) 2011-02-28
NO20041194L (no) 2004-03-19
ZA200400917B (en) 2004-08-25
CN1545423A (zh) 2004-11-10
TWI313609B (en) 2009-08-21
BR0212036A (pt) 2004-08-17
RU2275913C2 (ru) 2006-05-10
CA2457056C (en) 2008-07-22
WO2003015826A1 (en) 2003-02-27
CN100372570C (zh) 2008-03-05
HUP0401351A2 (hu) 2004-12-28
AU2002328093B2 (en) 2005-05-05
MXPA04001599A (es) 2004-07-08
CA2457056A1 (en) 2003-02-27
NZ530947A (en) 2006-04-28
AR035137A1 (es) 2004-04-14

Similar Documents

Publication Publication Date Title
HUP0401351A3 (en) Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence ofmaligant tumor
ZA200208163B (en) Pharmaceutical compositions comprising fluvastatin.
HUP0202513A3 (en) Betha-carboline pharmaceutical compositions
ZA200003997B (en) Pharmaceutical compositions.
GB0001662D0 (en) Pharmaceutical compositions
GB0028088D0 (en) Pharmaceutical compositions
GB9916536D0 (en) Nutritional or pharmaceutical compositions
GB0111597D0 (en) Pharmaceutical compositions
MXPA01010676A (es) Composicion farmaceutica de vitamina d o un analogo de vitamina d y al menos un corticoesteroide.
IL145290A0 (en) Pharmaceutical compositions comprising complexes
GB9923436D0 (en) Pharmaceutical compositions
ZA200210359B (en) Pharmaceutical compositions.
ZA200000857B (en) Pharmaceutical composition.
GB9904163D0 (en) Pharmaceutical compositions
MXPA03002105A (es) Composiciones farmaceuticas.
GB0104752D0 (en) Pharmaceutical compositions
GB9911017D0 (en) Pharmaceutical compositions
GB9904911D0 (en) Pharmaceutical compositions
HUP0200253A3 (en) Pharmaceutical compositions for combination therapy
GB2382302B (en) Pharmaceutical compositions
GB9902651D0 (en) Pharmaceutical compositions
ZA200110500B (en) Pharmaceutical composition.
MXPA03007318A (es) Composicion farmaceutica.
HK1065958A (en) Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor
ZA200110501B (en) Pharmaceutical composition.

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)